Trials / Unknown
UnknownNCT03158480
Safety and Efficacy of Immune Therapy for Condyloma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Shenzhen Second People's Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DC-CIK immunotherapy | Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients |
Timeline
- Start date
- 2017-06-25
- Primary completion
- 2018-12-31
- Completion
- 2019-06-30
- First posted
- 2017-05-18
- Last updated
- 2017-06-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03158480. Inclusion in this directory is not an endorsement.